UNIVERSITY OF ALABAMA AT BIRMINGHAM

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1969-01-01

Employees: 2K

Market Cap: -

Website: http://www.uab.edu

Clinical Trials

AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

Recruiting

Conditions: Amyotrophic Lateral Sclerosis
Multiple Sclerosis
Transverse Myelitis
Spinal Cord Injuries

First Posted Date: 2021-01-25

Last Posted Date: 2024-08-21

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 160

Registration Number: NCT04721717

Locations: 🇺🇸
354 School of Health Professions Building, Birmingham, Alabama, United States

Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)

Phase 2

Withdrawn

Conditions: COVID-19

Interventions: Biological: Thawed plasma

First Posted Date: 2021-01-25

Last Posted Date: 2021-06-30

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT04723589

Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE)

Not Applicable

Active, not recruiting

Conditions: Rheumatic Diseases

Interventions: Other: Tele-rheumatology

First Posted Date: 2021-01-11

Last Posted Date: 2024-12-27

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 652

Registration Number: NCT04704544

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Reducing Vertical Transmission of Hepatitis B in Africa

Phase 3

Recruiting

Conditions: Hepatitis B Infection

Interventions: Drug: Lamivudine Oral Solution
Drug: Tenofovir Disoproxil Fumarate

First Posted Date: 2021-01-11

Last Posted Date: 2024-10-18

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 450

Registration Number: NCT04704024

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

Phase 1

Terminated

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Ublituximab
Drug: Umbralisib

First Posted Date: 2020-12-31

Last Posted Date: 2023-09-28

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 1

Registration Number: NCT04692155

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

RA-PRO PRAGMATIC TRIAL

Phase 3

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: targeted synthetic DMARD class
Drug: non-TNFi-biologic class

First Posted Date: 2020-12-31

Last Posted Date: 2024-11-04

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 924

Registration Number: NCT04692493

Locations: 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Tufts University, Boston, Massachusetts, United States

and more 45 locations

Video Telehealth Exercise Training in Cystic Fibrosis

Not Applicable

Recruiting

Conditions: Cystic Fibrosis

Interventions: Other: Exercise

First Posted Date: 2020-12-23

Last Posted Date: 2025-02-04

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 25

Registration Number: NCT04680403

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa

Phase 4

Completed

Conditions: HIV Infections
Contraception
Drug-drug Interaction

Interventions: Device: Non-hormonal intrauterine device (IUD)
Drug: Etonogestrel (ETG) implant
Drug: Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
Drug: Sub-cutaneous medroxyprogesterone acetate (SC MPA)

First Posted Date: 2020-12-17

Last Posted Date: 2025-04-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 110

Registration Number: NCT04669678

Locations: 🇿🇦
Wits Reproductive Health and HIV Institute, Research Centre Clinical Research Site, Johannesburg, South Africa

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

Not yet recruiting

Conditions: Bone Loss

Interventions: Biological: E-PRF/rhBMP-2 (similar ratios)
Biological: rhBMP-2/E-PRF
Biological: E-PRF/ACS/rhBMP-2
Biological: E-PRF only

First Posted Date: 2020-12-17

Last Posted Date: 2025-02-12

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 20

Registration Number: NCT04670965

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

A Guided Online ACT Intervention Combined With Psychoeducation for People With Spinal Cord Injury

Not Applicable

Completed

Conditions: Spinal Cord Injuries
Psychological Distress

Interventions: Behavioral: acceptance and commitment therapy (ACT) combined with psychoeducation

First Posted Date: 2020-12-17

Last Posted Date: 2021-09-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 10

Registration Number: NCT04670406

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy